News

Filter

Dendreon leaps as it sets out plan to launch Provenge in Europe

Dendreon leaps as it sets out plan to launch Provenge in Europe

04-03-2014

US biotech firm Dendreon says it plans to make its prostate cancer drug Provenge (autologous peripheral…

BiotechnologyDendreonEuropeMarkets & MarketingOncologyProvenge

US physicians to increase use of Zytiga in chemo-naive prostate cancer patients

27-06-2012

Physicians in the USA said they would use Zytiga (abiraterone acetate), from health care giant Johnson…

DendreonJanssenJohnson & JohnsonMarkets & MarketingNorth AmericaOncologyPharmaceuticalProvengeResearchZytiga

Zytiga overtaking Provenge in MCRPC

17-01-2012

Despite no current approval of Johnson & Johnson (NYSE: JNJ) subsidiary Janssen’s Zytiga (abiraterone)…

BiotechnologyDendreonJanssenJevtanaJohnson & JohnsonMarkets & MarketingNorth AmericaOncologyPharmaceuticalProvengeSanofiZytiga

Dendreon upbeat on Provenge sales

08-01-2012

US biotech firm Dendreon (Nasdaq: DNDN) pleased investors last week when it reported that revenue of…

BiotechnologyDendreonFinancialMarkets & MarketingOncologyProvenge

Cancer vaccines market set to see change, will grow to over $9 billion by 2018

24-10-2011

The global cancer vaccines market in seven key markets (the USA, France, Germany, Italy, Spain, UK and…

CervarixDendreonGardasilGlaxoSmithKlineGlobalMarkets & MarketingMerck & CoOncologyPharmaceuticalProvengeVaccines

Johnson & Johnson’s Zytiga set to earn peak sales of $910 million for metastatic castrate-resistant prostate cancer; study

06-06-2011

US health care giant Johnson & Johnson’s (NYSE: JNJ) Zytiga (abiraterone acetate) will earn peak…

BiotechnologyDendreonJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalProvengeZytiga

Dendreon shares rise on plans to gain EU marketing approval for Provenge and US commercialization

10-01-2011

US biotech firm Dendreon (Nasdaq: DNDN) saw its shares rise 4.2% to $36.90 in early trading last Friday,…

BiotechnologyDendreonEuropeMarkets & MarketingNorth AmericaOncologyProvengeRegulation

COMPANY SPOTLIGHT

Menarini

Back to top